--- title: "Krystal Biotech (KRYS) news: lawsuit and settlement" url: "https://aibio.space/companies/krystal-biotech/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "KRYS lawsuit and settlement news. Krystal Biotech news for investors: Krystal Biotech sells Vyjuvek, a gene therapy for a rare skin disease, and is…" --- Desk view · Opinion · Updated Oct 22, 2026 ## Krystal Biotech has a profitable product and an unproven platform beyond skin Krystal has a profitable approved gene therapy and about $1.1 billion in cash, which funds a broad pipeline built on the same vector. The pipeline data are early, and Vyjuvek growth has slowed. This is analysis of public information, not advice. Read the full desk view aibio.space Investor Rank · Opinion **7** /10 Positive view Profitable on Vyjuvek with about $1.1 billion of cash, but Vyjuvek growth has slowed and the pipeline beyond skin is early. - **Technology**: 2/2 - **Odds**: 1/2 - **Balance sheet**: 2/2 - **Risk**: 1/2 - **Momentum**: 1/2 Opinion only. The Investor Rank is aibio.space's opinion of the company's business position, drawn from the public sources on this page. It is not a recommendation to buy, sell or hold any security and it is not investment advice. It does not consider the share price, valuation or your circumstances, and it can change at any time. Payments from companies never affect it. [How the rank works](https://aibio.space/disclosures/#rank). - **Technology**: **Proven in skin.** A herpes-virus vector delivers a gene in an approved product, but the lung and tumor uses are unproven. - **Odds**: **Pipeline is early.** Rare disease programs reach filing 60.4% of the time after phase 3, but KB407 and KB707 are in early studies of small patient groups. - **Balance sheet**: **Profitable and funded.** About $1.1 billion in cash and a $54.8 million quarterly profit, with no runway figure given. - **Main risk**: **One product carries the business.** Vyjuvek growth slowed to 24% in Q2 and European pricing talks are still open. - **Watch next**: **Q4 readout.** KB803 top-line data are due in the fourth quarter of 2026, and the company reports Q3 results on Nov. 2. ## Top news on Krystal 1. 2026-08-03 Legal [Krystal Biotech reports DOJ subpoenas on VYJUVEK testing program, director pay suit settlement](https://aibio.space/news/krystal-biotech-reports-doj-subpoenas-vyjuvek-testing-program-director/) The company and certain employees received Justice Department subpoenas in early 2025. A Delaware derivative suit over non-employee director pay has a fairness hearing set for September 14, 2026. 2. 2026-08-03 Legal [Krystal Biotech sued in Delaware over inventorship of two KB407 cystic fibrosis patents](https://aibio.space/news/krystal-biotech-sued-delaware-inventorship-two-kb407-cystic-fibrosis/) Jonathan Forman says he conceived of inventions claimed in two U.S. patents and was wrongly left off as an inventor. Krystal is the named defendant and says the claims are without merit. ## Dates **Nov 2, 2026** Third-quarter 2026 financial results [Source](https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-report-third-quarter-2026-financial-results) **Q4 2026** Top-line data from the KB803 IOLITE study; FDA alignment on KB407 registrational design [Source](https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-second-quarter-2026-financial-and) **Before end of 2026** Interim results from KB407 repeat-dose study, KB111 HALITE-1 and KB801 enrollment completion [Source](https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-second-quarter-2026-financial-and) **1H 2027** Updated interim data and registrational plans for inhaled KB707 in NSCLC [Source](https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-second-quarter-2026-financial-and) ## The money Cash, cash equivalents and investments of about $1.1 billion at June 30, 2026. 2026 non-GAAP R&D plus SG&A guided at $175 million to $195 million. No runway figure given. [Source](https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-second-quarter-2026-financial-and) Vyjuvek global net product revenue of $119.2 million in Q2 2026, up 24% from $96.0 million; $965.9 million cumulative since launch. [Source](https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-second-quarter-2026-financial-and) ## Risks on the record - Vyjuvek is the only marketed product; growth slowed to 24% year over year in Q2 2026 from 32% in Q1. [Source](https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-second-quarter-2026-financial-and) - Pricing negotiations in Germany continue through at least 2H 2026 and in France into 2027; UK launch awaits reimbursement. [Source](https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-second-quarter-2026-financial-and) - Pipeline data are small and uncontrolled: three patients in the KB113 pilot and seven in the highest-dose KB407 cohort. [Source](https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-positive-clinical-data-new-dermatology) ## Questions investors ask ### What is aibio.space's Investor Rank for Krystal Biotech? 7 out of 10, our positive view. Profitable on Vyjuvek with about $1.1 billion of cash, but Vyjuvek growth has slowed and the pipeline beyond skin is early. This is opinion only, not a recommendation to buy, sell or hold, and it does not consider the share price or valuation. [Source](https://aibio.space/disclosures/#rank) ### What does Krystal Biotech make? Krystal sells Vyjuvek, a gene therapy for dystrophic epidermolysis bullosa, a rare blistering skin disease. It is approved in the US, EU, Japan and, since May 2026, the UK. [Source](https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-united-kingdom-mhra-approval-vyjuvekr) ### How much revenue does Vyjuvek generate? Vyjuvek brought in $119.2 million in global net product revenue in the second quarter of 2026, up 24% from a year earlier. Cumulative revenue since launch is $965.9 million. [Source](https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-second-quarter-2026-financial-and) ### Is Krystal Biotech profitable? Yes. The company reported second-quarter 2026 net income of $54.8 million, with a 95% gross margin. It held about $1.1 billion in cash, cash equivalents and investments at June 30. [Source](https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-second-quarter-2026-financial-and) ### What did the KB113 Gorlin syndrome data show? In a three-patient pilot, 83.1% of 83 basal cell carcinoma lesions showed some regression, including lesions that were not injected. Adverse events were mild or moderate. The study was small, single-arm and open-label. [Source](https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-positive-clinical-data-new-dermatology) ### When does Krystal Biotech report earnings next? Krystal will report third-quarter 2026 financial results on Nov. 2, 2026. KB803 top-line data from the IOLITE study are expected in the fourth quarter. [Source](https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-report-third-quarter-2026-financial-results) ### What is the latest Krystal Biotech (KRYS) stock news? Our latest story on Krystal Biotech, dated Aug 3, 2026: "Krystal Biotech reports DOJ subpoenas on VYJUVEK testing program, director pay suit settlement". The company and certain employees received Justice Department subpoenas in early 2025. A Delaware derivative suit over non-employee director pay has a fairness hearing set for September 14, 2026. [Source](https://aibio.space/news/krystal-biotech-reports-doj-subpoenas-vyjuvek-testing-program-director/) ### Is Krystal Biotech facing a lawsuit? Our latest legal story, dated Aug 3, 2026: "Krystal Biotech reports DOJ subpoenas on VYJUVEK testing program, director pay suit settlement". The company and certain employees received Justice Department subpoenas in early 2025. A Delaware derivative suit over non-employee director pay has a fairness hearing set for September 14, 2026. Claims in lawsuits are allegations until a court rules. [Source](https://aibio.space/news/krystal-biotech-reports-doj-subpoenas-vyjuvek-testing-program-director/) ### What is Krystal Biotech's market cap? We do not publish live share prices. In its annual report, Krystal Biotech, Inc. put the market value of shares held by non-affiliates (public float) at $3.50 billion as of Jun 30, 2025. Source ### Is Krystal Biotech a smaller reporting company? SEC records list Krystal Biotech, Inc.'s filer category as: Large accelerated filer. Source ### Where is Krystal Biotech headquartered? SEC records list its business address as 2100 WHARTON STREET, PITTSBURGH, PA, 15203. Source ### When does Krystal Biotech's fiscal year end? Krystal Biotech, Inc.'s fiscal year ends on December 31, per SEC records. Source ### What did Krystal Biotech last file with the SEC? Its most recent filing in our record is an 8-K filed 2026-10-15. All of its filings are on SEC EDGAR. [Source](https://www.sec.gov/Archives/edgar/data/1711279/000171127926000064/krys-20261015.htm) ### What industry is Krystal Biotech in? Its SEC industry code (SIC 2836) is Biological Products, (No Diagnostic Substances). Source ### How can I follow Krystal Biotech (KRYS) news? Press Follow on this page to add Krystal Biotech to your Following list, or subscribe to the aibio.space newsletter. We have published 2 stories naming Krystal Biotech so far, in Legal. Source ## Legal and investor matters Checked against Krystal Biotech filings and press releases. Allegations are allegations; nothing here is a finding of fault. Reviewed Oct 25, 2026. 1. 2026-08-03 Derivative suit Krystal director-pay derivative suit settlement is set for a September 14, 2026 fairness hearing Krystal's 10-Q filed August 3, 2026 says the parties to a derivative suit in the Delaware Court of Chancery entered into a settlement agreement, subject to court approval after a fairness hearing scheduled for September 14, 2026. If approved, the company will adopt and maintain certain corporate governance reforms for five years. The company recorded a liability for the plaintiff's attorneys' fees and expenses, which it describes as not material. Delaware Court of Chancery · Status: pending [Krystal Biotech 10-Q filed 2026-08-03](https://www.sec.gov/Archives/edgar/data/1711279/000171127926000057/krys-20260630.htm) 2. 2026-05-29 Litigation Inventorship suit filed against Krystal over two KB407 cystic fibrosis patents Krystal reported in its 10-Q that on May 29, 2026 Jonathan Forman filed a lawsuit against it in the U.S. District Court for the District of Delaware, Docket No. 1:26-cv-00628. The complaint seeks correction of inventorship on two patents that the plaintiff alleges are embodied in the KB407 cystic fibrosis candidate. He alleges he was erroneously omitted as a named inventor. Krystal believes the claims are without merit and cannot estimate a loss. U.S. District Court for the District of Delaware · Case 1:26-cv-00628 · Status: filed [Krystal Biotech 10-Q filed 2026-08-03](https://www.sec.gov/Archives/edgar/data/1711279/000171127926000057/krys-20260630.htm) 3. 2025-09-18 Derivative suit Stockholder files Delaware derivative suit over Krystal non-employee director pay Krystal reported in its 10-Q filed November 3, 2025 that on September 18, 2025 a purported stockholder filed a derivative complaint in the Delaware Court of Chancery against the company's directors, naming the company as nominal defendant. The complaint alleges claims for breach of fiduciary duty, unjust enrichment and waste of corporate assets. The claims rest on allegedly excessive non-employee director compensation in 2021 through 2024. Delaware Court of Chancery · Status: filed [Krystal Biotech 10-Q filed 2025-11-03](https://www.sec.gov/Archives/edgar/data/1711279/000171127925000087/krys-20250930.htm) 4. 2025-05-06 Regulatory Krystal discloses DOJ subpoenas on Vyjuvek genetic testing program In its 10-Q filed May 6, 2025, Krystal disclosed that in the first quarter of 2025 it and certain employees received subpoenas from the U.S. Department of Justice. The subpoenas request documents on its sponsored genetic testing program for Vyjuvek and related commercial practices. Krystal says it is cooperating and that it is not possible to estimate any loss. The 10-Q filed August 3, 2026 continues to describe the matter. Status: pending [Krystal Biotech 10-Q filed 2025-05-06](https://www.sec.gov/Archives/edgar/data/1711279/000171127925000044/krys-20250331.htm) ## Pipeline | Program | Indication | Stage | |---|---|---| | Vyjuvek (beremagene geperpavec) | Dystrophic epidermolysis bullosa | Approved in the US (May 2023), EU (April 2025), Japan (July 2025) and UK (May 2026) [Source](https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-united-kingdom-mhra-approval-vyjuvekr) | | KB803 | Corneal abrasions in dystrophic epidermolysis bullosa | Registrational IOLITE study fully enrolled; top-line data expected Q4 2026 [Source](https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-second-quarter-2026-financial-and) | | KB801 | Neurotrophic keratitis | EMERALD-1 enrolling about 60 patients; enrollment to finish before year end 2026 [Source](https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-second-quarter-2026-financial-and) | | KB407 (inhaled) | Cystic fibrosis | Phase 1 (CORAL-1); FDA alignment on registrational design expected Q4 2026 [Source](https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-second-quarter-2026-financial-and) | | KB707 (inhaled and intratumoral) | Non-small cell lung cancer; basal cell carcinoma | Phase 1/2 (KYANITE-1, OPAL-1); RMAT designation for inhaled KB707 in NSCLC [Source](https://www.cancernetwork.com/view/fda-grants-rmat-designation-to-hsv-based-immunotherapy-in-nsclc) | | KB113 (low-dose intratumoral KB707) | Basal cell carcinoma in Gorlin syndrome | Three-patient pilot completed; FDA discussions started [Source](https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-positive-clinical-data-new-dermatology) | Opinion · Devil's advocate ## Fact-check-o-meter Some gaps Vyjuvek numbers hold up; the new Gorlin data are thinner than the release reads Krystal's revenue and cash figures match its 10-Q, and the company flagged an earlier KB801 data point itself. The KB113 release leads with a lesion response rate built on three open-label patients, and the legal matters in the 10-Q, including DOJ subpoenas tied to Vyjuvek, were not in the quarterly results release. 1. Science · weight medium Headline response rate counts any shrinkage in 3 patients **The company said:** "Broad antitumor responses were detected in all three Gorlin syndrome patients treated with KB113, with over 80% of assessed BCC lesions reducing in size;" [source](https://www.sec.gov/Archives/edgar/data/1711279/000171127926000064/krystalgorlinprogramdataup.htm) **The record says:** The same release's table shows 69/83 (83.1%) lesions with "Any clinical regression in lesion size", 42/83 (50.6%) with more than 50% regression and 8/83 (9.6%) with at least 90% regression. It describes the study as "a multicenter, single-arm, open label study" in which "The investigator selected which landmark lesions to inject" and regression was judged on an "investigator-assessed 5-point clearance scale". [source](https://www.sec.gov/Archives/edgar/data/1711279/000171127926000064/krystalgorlinprogramdataup.htm) **Our view:** The 80% figure is true as stated, but it includes any shrinkage at all. About one lesion in ten reached 90% regression. With three patients, no control arm and the investigator both choosing and grading lesions, this is a first signal, not efficacy data. 2. Science · weight medium Histology confirmed response only in lesions already doing best **The company said:** "Complete clearance of an injected lesion was also confirmed histologically for each of the three patients treated with KB113." [source](https://www.sec.gov/Archives/edgar/data/1711279/000171127926000064/krystalgorlinprogramdataup.htm) **The record says:** The release explains: "To further assess clinical regression, one injected lesion from each patient that had achieved at least 90% clinical regression was biopsied." The release cites no registry entry for the Gorlin pilot study itself. The OPAL-1 record it points to (NCT05970497) covers the separate KB707 phase 1/2 solid tumor study and lists two primary outcomes, "Percentage of adverse events (AEs)" and "Percentage of serious adverse events (SAEs)", and an estimated enrollment of 240. [source](https://clinicaltrials.gov/study/NCT05970497) **Our view:** Three biopsies from the best-responding lesions show the drug can clear a tumor. They say little about how often it does. The OPAL-1 registry primary outcomes are safety only and the release gives no registry record for the Gorlin pilot, so the response analysis here is preliminary. 3. Press release vs filing · weight low $1.1 billion headline versus the 10-Q's narrower cash line **The company said:** "Cash, cash equivalents and investments totaled $1.1 billion as of June 30, 2026" [source](https://www.sec.gov/Archives/edgar/data/1711279/000171127926000058/a2q26-ex991xpressrelease.htm) **The record says:** The 10-Q says: "As of June 30, 2026, our cash, cash equivalents and short-term investments balance was approximately $845.6 million". The balance sheet in the release lists $257,291 thousand of long-term investments on top of that. [source](https://www.sec.gov/Archives/edgar/data/1711279/000171127926000057/krys-20260630.htm) **Our view:** Both numbers are right. The difference is long-term investments of about $257 million, which the 10-Q leaves out when it says the cash is enough for at least 12 months. The filing's 12-month funding statement uses the narrower $845.6 million figure. 4. Press release vs filing · weight low An earlier KB801 study surfaced through a patent filing **The company said:** "The Company continues to enroll in EMERALD-1, the Company's registrational, 1:1 randomized, double-masked, multicenter, placebo-controlled study evaluating KB801 for the treatment of NK." [source](https://www.sec.gov/Archives/edgar/data/1711279/000171127926000058/a2q26-ex991xpressrelease.htm) **The record says:** A July 21 8-K says a patent response "included data from a patient who received KB801 in a discontinued clinical study" and that "The Company did not previously disclose the single-patient observation described above". It adds that "no conclusions regarding the safety or efficacy of KB801 should be drawn from it." [source](https://www.sec.gov/Archives/edgar/data/1711279/000171127926000050/krys-20260721.htm) **Our view:** The company flagged the patent-record data itself, which is the right move. The Aug. 3 release describes EMERALD-1 without mentioning the discontinued study, and the 8-K gives no results beyond one patient, so the earlier data stay thin. 5. Legal and disclosure record · weight medium DOJ subpoenas, a derivative suit with a proposed settlement and a patent inventorship suit in the 10-Q **The record says:** The Q2 10-Q's legal note says the company and certain employees "received subpoenas from the U.S. Department of Justice requesting that the Company produce certain documents regarding its sponsored genetic testing program relating to VYJUVEK" and that it is cooperating. It also describes a derivative complaint filed September 18, 2025 in the Delaware Court of Chancery over director pay, with a settlement subject to a fairness hearing scheduled for September 14, 2026, and a May 29, 2026 inventorship suit by Jonathan Forman in the U.S. District Court for the District of Delaware (Docket No. 1:26-cv-00628) over patents that the plaintiff alleges are embodied in KB407. [source](https://www.sec.gov/Archives/edgar/data/1711279/000171127926000057/krys-20260630.htm) **Our view:** The DOJ inquiry concerns the commercial practices behind the one product that generates the revenue, and the filing says no loss can be estimated. The Aug. 3 results release did not mention these matters. We did not review the later court outcome of the settlement hearing. Documents we compared - [Press release: KB113 Gorlin syndrome data (8-K exhibit 99.1)](https://www.sec.gov/Archives/edgar/data/1711279/000171127926000064/krystalgorlinprogramdataup.htm) 2026-10-15 - [Press release: Q2 2026 results (8-K exhibit 99.1)](https://www.sec.gov/Archives/edgar/data/1711279/000171127926000058/a2q26-ex991xpressrelease.htm) 2026-08-03 - [Form 10-Q for the quarter ended June 30, 2026](https://www.sec.gov/Archives/edgar/data/1711279/000171127926000057/krys-20260630.htm) 2026-08-03 - [Form 8-K: KB801 single-patient disclosure](https://www.sec.gov/Archives/edgar/data/1711279/000171127926000050/krys-20260721.htm) 2026-07-21 - [Form 8-K: KB113 current report](https://www.sec.gov/Archives/edgar/data/1711279/000171127926000064/krys-20261015.htm) 2026-10-15 - [ClinicalTrials.gov NCT05970497 (OPAL-1)](https://clinicaltrials.gov/study/NCT05970497) 2025-05-18 This is opinion. We compare the company's own announcements with its filings and the scientific record, and link every source. It is not an allegation of wrongdoing and not investment or legal advice. Legal items list only matters disclosed in filings or by courts and regulators. Checked Oct 23, 2026. Companies can respond through our [right of reply](https://aibio.space/reputation/#reply). ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:KRYS on TradingView](https://www.tradingview.com/symbols/NASDAQ-KRYS/). ## SEC filings and registration - **SEC name**: Krystal Biotech, Inc. - **CIK**: 1711279 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: KRYS (Nasdaq) - **Fiscal year ends**: December 31 - **Filer category**: Large accelerated filer - **Business address**: 2100 WHARTON STREET, PITTSBURGH, PA, 15203 - **Phone**: (412) 586-5830 - **Shares outstanding**: 29,598,836 as of 2026-07-28 (10-Q filed 2026-08-03) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1711279/000171127926000064/krys-20261015.htm) filed 2026-10-15 - [8-K](https://www.sec.gov/Archives/edgar/data/1711279/000171127926000058/krys-20260803.htm) filed 2026-08-03 - [10-Q](https://www.sec.gov/Archives/edgar/data/1711279/000171127926000057/krys-20260630.htm) filed 2026-08-03 - [8-K](https://www.sec.gov/Archives/edgar/data/1711279/000171127926000050/krys-20260721.htm) filed 2026-07-21 - [8-K](https://www.sec.gov/Archives/edgar/data/1711279/000171127926000047/krys-20260515.htm) filed 2026-05-20 - [8-K](https://www.sec.gov/Archives/edgar/data/1711279/000171127926000044/krys-20260504.htm) filed 2026-05-04 - [10-Q](https://www.sec.gov/Archives/edgar/data/1711279/000171127926000043/krys-20260331.htm) filed 2026-05-04 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1711279/000171127926000036/krys-20260403.htm) filed 2026-04-03 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001711279), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/krystal-biotech/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Krystal Biotech (KRYS) news: lawsuit and settlement", 2026-10-31, https://aibio.space/companies/krystal-biotech/